腎臓移植治療法の世界市場2019-2023

【英語タイトル】Kidney Transplantation Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

Technavioが出版した調査資料(IRTNTR31945)・商品コード:IRTNTR31945
・発行会社(調査会社):Technavio
・発行日:2019年8月28日
・ページ数:129
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
Technavio社の本調査レポートでは、腎臓移植治療法の世界市場について調べ、腎臓移植治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、腎臓移植治療法の市場規模をセグメンテーション別(製品別(選択的サイトカイン阻害剤、免疫抑制性代謝拮抗薬、他の薬)、)と地域別(グローバル、アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は腎臓移植治療法の世界市場規模が2019-2023期間中に年平均4%成長すると予測しています。
・サマリー
・レポートの範囲
・腎臓移植治療法の市場状況
・腎臓移植治療法の市場規模
・腎臓移植治療法の市場予測
・腎臓移植治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(選択的サイトカイン阻害剤、免疫抑制性代謝拮抗薬、他の薬)
・腎臓移植治療法の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Kidney Transplantation Therapeutics Market: About this market
Technavio’s kidney transplantation therapeutics market analysis considers sales from selective cytokine inhibitors, immunosuppressive antimetabolites, and other drugs. Our analysis also considers the sales of kidney transplantation therapeutics in Asia, Europe, North America, and ROW. In 2018, the selective cytokine inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as superior immunosuppressive capabilities will play a significant role in the selective cytokine inhibitors segment to maintain its market position. Also, our global kidney transplantation therapeutics market report looks at factors such as the rising prevalence of CKD and renal impairments, availability of drugs in multiple dosage forms, and high dependency on immunosuppressants for kidney transplantations. However, side-effects of immunosuppressants, demand-supply imbalance, and stringent regulatory guidelines may hamper the growth of the kidney transplantation therapeutics industry over the forecast period.

Global Kidney Transplantation Therapeutics Market: Overview

High dependency on immunosuppressants for kidney transplantation
Significant advances in surgical techniques and ancillary healthcare techniques are increasing the demand for kidney transplantation. To overcome the challenge of transplant rejection, vendors have developed immunosuppressants. Thus, to reduce the risk and probability of the transplanted organ getting rejected, patients must undergo maintenance therapy using these immunosuppressants for the rest of their lives. This increase in the kidney transplantation and risks associated raises the demand for immunosuppressants leading to the expansion of the global kidney transplantation therapeutics market at a CAGR of over 4% during the forecast period.

Reimbursement policies for kidney transplantation
Patient assistance programs make drugs affordable for patients. These programs are associated with both government and non-government organizations. The Patient Protection and Affordable Care Act aims to improve the quality of health care by providing affordable health insurance. Similarly, the Medicare insurance coverage is expected to enable patients to take immunosuppressants on daily basisdaily to reduce the risk of transplant rejection for years after the transplantation as it is challenging to afford the costs associated with this therapy. Such initiatives are expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global kidney transplantation therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global kidney transplantation therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading kidney transplantation therapeutics manufacturers, that include Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Mylan NV, Novartis AG, Veloxis Pharmaceuticals A/S.

Also, the kidney transplantation therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Selective cytokine inhibitors – Market size and forecast 2018-2023
• Immunosuppressive antimetabolites – Market size and forecast 2018-2023
• Other drugs – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Novel techniques for kidney transplantation
• Reimbursement policies for kidney transplantation
• Increasing strategic alliances
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Astellas Pharma, Inc.
• F. Hoffmann-La Roche Ltd.
• Mylan NV
• Novartis AG
• Veloxis Pharmaceuticals A/S
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO

Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Selective cytokine inhibitors – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Selective cytokine inhibitors – Year-over-year growth 2019-2023 (%)
Exhibit 22: Immunosuppressive antimetabolites – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Immunosuppressive antimetabolites – Year-over-year growth 2019-2023 (%)
Exhibit 24: Other drugs – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Other drugs – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Astellas Pharma Inc. – Vendor overview
Exhibit 51: Astellas Pharma Inc. – Business segments
Exhibit 52: Astellas Pharma Inc. – Organizational developments
Exhibit 53: Astellas Pharma Inc. – Geographic focus
Exhibit 54: Astellas Pharma Inc. – Key offerings
Exhibit 55: Astellas Pharma Inc. – Key customers
Exhibit 56: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 57: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 58: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 59: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 60: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 61: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 62: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 63: Mylan NV – Vendor overview
Exhibit 64: Mylan NV – Product segments
Exhibit 65: Mylan NV – Organizational developments
Exhibit 66: Mylan NV – Geographic focus
Exhibit 67: Mylan NV – Segment focus
Exhibit 68: Mylan NV – Key offerings
Exhibit 69: Mylan NV – Key customers
Exhibit 70: Novartis AG – Vendor overview
Exhibit 71: Novartis AG – Business segments
Exhibit 72: Novartis AG – Organizational developments
Exhibit 73: Novartis AG – Geographic focus
Exhibit 74: Novartis AG – Segment focus
Exhibit 75: Novartis AG – Key offerings
Exhibit 76: Novartis AG – Key customers
Exhibit 77: Veloxis Pharmaceuticals A/S – Vendor overview
Exhibit 78: Veloxis Pharmaceuticals A/S – Business segments
Exhibit 79: Veloxis Pharmaceuticals A/S – Organizational developments
Exhibit 80: Veloxis Pharmaceuticals A/S – Geographic focus
Exhibit 81: Veloxis Pharmaceuticals A/S – Key offerings
Exhibit 82: Veloxis Pharmaceuticals A/S – Key customers
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of market positioning of vendors



【掲載企業】

Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Mylan NV, Novartis AG, and Veloxis Pharmaceuticals A/S.

★調査レポート[腎臓移植治療法の世界市場2019-2023] (コード:IRTNTR31945)販売に関する免責事項を必ずご確認ください。
★調査レポート[腎臓移植治療法の世界市場2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆